reports
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxfor...
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Up to $200 million financing, includes $50 million upfront REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. “This financing significantly strengthens our financial position, providing additional supp...
Dollar General Corp: 1 director
A director at Dollar General Corp sold 4,740 shares at 77.439USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MYE MYERS INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
MEDP MEDPACE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
CULP CULP INC.
PETS PETMED EXPRESS INC.
SCVL SHOE CARNIVAL INC.
TREE LENDINGTREE INC.
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
DBI DESIGNER BRANDS INC. CLASS A
ORGO ORGANOGENESIS HOLDINGS (A)
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
RZLT REZOLUTE
RVMD INC.
SSSS REVOLUTION MEDICINES
FTHM SUTTER ROCK CAPITAL CORP.
GNSS FATHOM HOLDINGS
CTGO GENASYS INC
AGL CONTANGO ORE INC.
NOTV AGILON HEALTH
AUID INC.
TRIN INOTIV
TCBX INC.
IBRX IPSIDY INC.
BIGZ TRINITY CAPITAL INC
MODD THIRD COAST BANCSHARES INC
GRNT IMMUNITYBIO INC
UAMY BLACKROCK INNOVATION AND GROWTH TST
TKO MODULAR MEDICAL INC
SRBK GRANITE RIDGE RESOURCES INC
NCDL U S ANTIMONY CORP
SPRU TKO GROUP HOLDINGS
AVDL INC.
CATX SR BANCORP INC
MRAI NUVEEN CHURCHILL DIRECT LENDING CORP
GWAV SPRUCE POWER HOLDING CORP
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PERSPECTIVE THERAPEUTICS
INC.
MARPAI
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
LPSN LIVEPERSON INC.
NSC NORFOLK SOUTHERN CORPORATION
UONEK URBAN ONE INC CLASS D
GNSS GENASYS INC
AGL AGILON HEALTH
MAIA INC.
SES MAIA BIOTECHNOLOGY INC
TKO SES AI CORPORATION
TKO GROUP HOLDINGS
INC.
Oxbridge / SurancePlus Announces Upcoming Participation in Key Industr...
Oxbridge / SurancePlus Announces Upcoming Participation in Key Industry Events GRAND CAYMAN, Cayman Islands, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiaries, is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States. Today, announced its upcoming participation in several key industry events alongside its Web3-focused subsidiary, SurancePlus Inc. (“SurancePlus”), highlighting...
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Health...
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’...
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR ...
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome PDUFA target action date extended by three months to March 27, 2025 REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extende...
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide C...
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, bein...
Oxbridge Re Reports Update on its RWA Tokenized Security, its Business...
Oxbridge Re Reports Update on its RWA Tokenized Security, its Business and Third Quarter 2024 Results GRAND CAYMAN, Cayman Islands, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), together with its subsidiaries which is engaged in the business of tokenized Real-World Assets (“RWAs”) initially in the form of tokenized reinsurance securities, and reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, reported its results for the three and nine months ended September 30, 2024. “We are energized by the progress of our Web3/RWA s...
Design Therapeutics to Participate in Multiple Upcoming Investor Confe...
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024, at 11:30 ...
- Jonathan Moreland
LOGI LOGITECH INTERNATIONAL S.A.
TCBI TEXAS CAPITAL BANCSHARES INC.
RRGB RED ROBIN GOURMET BURGERS INC.
PPSI PIONEER POWER SOLUTIONS
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
CROX CROCS INC.
AIN ALBANY INTERNATIONAL CORP. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
ATLO AMES NATIONAL CORP.
TAYD TAYLOR DEVICES INC.
FBK FB FINANCIAL CORPORATION
CDZI CADIZ INC.
JELD JELD-WEN HOLDING INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR SLEEP NUMBER CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
MEC MAYVILLE ENGINEERING
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
TELA TELA BIO
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
BDSX BIODESIX
MODV MODIVCARE INC
UAN CVR PARTNERS LP
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TRIN TRINITY CAPITAL INC
BGS B&G FOODS
NRDS INC.
MAIA NERDWALLET INC
SKYH MAIA BIOTECHNOLOGY INC
MBLY SKY HARBOUR GROUP CORP
NE MOBILEYE GLOBAL INC
CALC NOBLE CORP (NEW)
BYON CALCIMEDICA INC.
DRUG BEYON 3D LTD
IKT BRIGHT MINDS BIOSCIENCES INC
ARR INHIBIKASE THERAPEUTICS INC.
MIO ARMOUR RESIDENTIAL REIT INC.
OI PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
WPC OWENS ILLINOIS INC.
UMAC W. P. CAREY AND CO. LLC
EVM UNUSUAL MACHS INC NEV
PDYN EATON VANCE INSD CALIF MUN BD FD
SARCOS TECHNOLOGY AND ROBOTICS CORP
Design Therapeutics Announces Third Quarter 2024 Financial Results and...
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Cli...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarte...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi sy...
- Jonathan Moreland
ETSY ETSY INC.
AIN ALBANY INTERNATIONAL CORP. CLASS A
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
NANX NANOPHASE TECHNOLOGIES CORP.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
EPIX EPIX PHARMACEUTICALS
TRIN TRINITY EXPLORATION & PRODUCTION
CALC CALCIMEDICA INC.
SES SES AI CORPORATION
BTM BITCOIN DEPOT INC
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
WPC W. P. CAREY AND CO. LLC
Oxbridge / SurancePlus CEO Jay Madhu to Speak at Digital Assets Week i...
Oxbridge / SurancePlus CEO Jay Madhu to Speak at Digital Assets Week in Singapore GRAND CAYMAN, Cayman Islands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge”), together with its RWA/Web3-focused subsidiary, (“SurancePlus”), today announced it will be participating in two of the world’s most anticipated events regarding digital assets and fintech. Oxbridge Re, together with its subsidiary SurancePlus is engaged in the business of tokenized Real-World Assets (“RWAs”) initially in the form of reinsurance securities, and providing reinsurance solutions to property and casualty in...
Oxbridge Re Announces 2024 Third Quarter Results on November 13, 2024
Oxbridge Re Announces 2024 Third Quarter Results on November 13, 2024 GRAND CAYMAN, Cayman Islands, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Oxbridge Re (NASDAQ: ) announced that it plans to hold a conference call on Wednesday November 13, 2024 at 4:30 p.m. Eastern time to discuss results for the third quarter and nine months ending ended September 30, 2024. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge Re’s management will host the conference call, followed by a question and answer period. Interested parties can listen to the li...
Soleno Therapeutics to Participate in Upcoming November Investor Confe...
Soleno Therapeutics to Participate in Upcoming November Investor Conferences REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Even...
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Ma...
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno’s (formerly Capnia’s) Chairman from 2007 through August 2024. "On behalf of the Board of Directors and the entire Soleno family,...
- Jonathan Moreland
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.